Rectify Pharma
PrivateLast Round
Strategic
Dec 22, 2025
Total Funding Raised
$100M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Rectify Pharma operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Strategic round in December 2025.
Rectify Pharma is a biotechnology company developing disease-modifying precision therapies through positive functional modulators that restore ABC transporter function to treat genetic disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Rectify Pharma Comparables
Compare Rectify Pharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Maze Therapeutics | 73% | |
| Novartis | 70% | |
| Judo Bio | 61% |
For institutional investors. Book with your work email.
Rectify Pharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Dec 22, 2025 | ||||
| Series A | Oct 14, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Rectify Pharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Boehringer Ingelheim | Strategic |
| Omega Funds | Series A |
| Dean Capital Investments Management | Series A |
| Forbion | Series A |
| Atlas Venture | Series A |
| Longwood Fund | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 5, 2026
Presented data at The Liver Meeting (AASLD) in Denver.
- Nov 5, 2026
Presented preclinical data for RTY-406 at The Liver Meeting® 2026.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventNov 5, 2026
Rectify Pharma attends The Liver Meeting(R), the Annual Meeting of the American Association for the Study of Liver Diseases, and presents preclinical data on RTY-406 in Colorado on Nov 7th '26.
- attends_eventNov 5, 2026
Rectify Pharma is scheduled to present preclinical data characterizing RTY-406 at The Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Diseases, in Colorado on Nov 7th '26.
- attends_eventNov 5, 2026
Rectify Pharma presents preclinical data characterizing RTY-406 during the Industry Research Showcase at AASLD 2026 Liver Meeting in Colorado on Nov 7th '26.
- attends_eventOct 24, 2026
Rectify Pharma presents preclinical RTY-406 data during the Industry Research Showcase in Colorado on Nov 7th '26, with Eric Bell, PhD, delivering the presentation.
- is_developingOct 22, 2026
Rectify Pharma is advancing Positive Functional Modulators (PFMs), oral small molecules that restore and enhance membrane protein function to address the underlying cause of serious diseases; RTY-406 is in Phase 1 clinical trials, with data from cholestatic patients anticipated in 2027.
For institutional investors. Book with your work email.
Rectify Pharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Rectify Pharma's valuation, stock price, and market status.
Is Rectify Pharma a public or private company?
Rectify Pharma is a private company.
What is the current stock price of Rectify Pharma?
Rectify Pharma is a private company, so its shares have no public market price. Caplight tracks Rectify Pharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Rectify Pharma worth (valuation)?
Valuation information for Rectify Pharma is not publicly available.
Can I buy Rectify Pharma stock?
Rectify Pharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Rectify Pharma's last funding round?
Rectify Pharma's most recent funding round was Strategic on December 22, 2025.
Who are the main investors in Rectify Pharma?
Key investors in Rectify Pharma include Omega Funds, Forbion, Atlas Venture, Longwood Fund.
Will Rectify Pharma IPO soon?
No public IPO plans have been announced for Rectify Pharma.
How can I track Rectify Pharma secondary market activity?
Caplight tracks bids, offers, and trades in Rectify Pharma's shares on secondary markets.